Premenopausal women | Postmenopausal women | |||
---|---|---|---|---|
Cases | Controls | Cases | Controls | |
N = 553 | N = 623 | N = 282 | N = 340 | |
Age, median (25th, 75th percentile) | 45 (40, 48) | 42 (37, 47) | 59 (55, 63) | 57 (53, 62) |
Recruitment site | ||||
Memorial Sloan Kettering Cancer Center | 373 (67%) | 431 (69%) | 165 (59%) | 223 (66%) |
University of Pennsylvania Medical Center | 65 (12%) | 67 (11%) | 44 (16%) | 50 (15%) |
University of Utah Huntsman Cancer Institute | 115 (21%) | 125 (20%) | 73 (26%) | 67 (20%) |
Menopausal status and reasona | ||||
Premenopausal | 537 (97%) | 597 (96%) | ||
Premenopausal (simple hysterectomy) | 16 (3%) | 26 (4%) | ||
Postmenopausal (natural) | 212 (75%) | 207 (61%) | ||
Postmenopausal (oophorectomy) | 25 (9%) | 93 (27%) | ||
Postmenopausal (simple hysterectomy) | 38 (13%) | 37 (11%) | ||
Postmenopausal (reason unknown) | 7 (3%) | 3 (1%) | ||
Race/ethnicity | ||||
Non-Hispanic White | 451 (81%) | 513 (82%) | 227 (80%) | 301 (89%) |
Non-Hispanic Black | 31 (6%) | 24 (4%) | 17 (6%) | 14 (4%) |
Non-Hispanic Asian | 31 (6%) | 26 (4%) | 15 (5%) | 10 (3%) |
Non-Hispanic (another race) | 10 (2%) | 16 (3%) | 3 (1%) | 3 (1%) |
Hispanic (any race) | 30 (5%) | 44 (7%) | 20 (8%) | 12 (3%) |
Ever smoker | ||||
Never | 426 (77%) | 485 (78%) | 194 (69%) | 254 (75%) |
Ever | 127 (23%) | 138 (22%) | 88 (31%) | 86 (25%) |
Body mass index at time of MRIb (kg/m2) | ||||
< 25 | 346 (63%) | 400 (64%) | 113 (40%) | 208 (61%) |
25 to < 30 | 121 (22%) | 143 (23%) | 96 (34%) | 67 (20%) |
≥ 30 | 85 (15%) | 78 (13%) | 73 (26%) | 64 (19%) |
Unknown | 1 | 2 | 0 | 1 |
Parity | ||||
0 | 194 (35%) | 230 (37%) | 67 (24%) | 83 (24%) |
1 | 89 (15%) | 77 (12%) | 49 (17%) | 50 (15%) |
2+ | 270 (50%) | 316 (51%) | 166 (59%) | 197 (61%) |
Family history of breast cancerc | ||||
No | 399 (77%) | 210 (34%) | 181 (68%) | 103 (31%) |
Yes | 116 (23%) | 399 (66%) | 85 (32%) | 231 (69%) |
Unknown (n) | 38 | 14 | 16 | 6 |
BRCA1 mutationd | ||||
Negative | 340 (66%) | 202 (33%) | 99 (36%) | 127 (39%) |
Positive | 9 (1.7%) | 78 (13%) | 4 (1.4%) | 29 (8.8%) |
Not tested | 166 (32%) | 329 (54%) | 173 (63%) | 173 (53%) |
Unknown | 38 | 14 | 6 | 11 |
BRCA2 mutationd | ||||
Negative | 340 (66%) | 202 (33%) | 95 (34%) | 105 (32%) |
Positive | 9 (1.7%) | 78 (13%) | 8 (2.9%) | 51 (16%) |
Not tested | 166 (32%) | 329 (54%) | 173 (63%) | 173 (53%) |
Unknown | 38 | 14 | 6 | 11 |
History of LCIS | ||||
No | 546 (99%) | 584 (94%) | 274 (97%) | 302 (89%) |
Yes | 7 (1%) | 39 (6%) | 8 (3%) | 38 (11%) |
History of benign breast disease | ||||
No | 443 (80%) | 332 (53%) | 210 (74%) | 160 (47%) |
Yes | 110 (20%) | 291 (47%) | 72 (26%) | 180 (53%) |
MRIfibroglandular tissue | ||||
Almost entirely fat | ||||
Scattered FGT | ||||
Characteristics of cases | N = 553 | N = 282 | ||
Estrogen receptor | ||||
Negative | 88 (16%) | 59 (21%) | ||
Positive | 462 (84%) | 222 (79%) | ||
Unknown | 3 | 1 | ||
Progesterone receptor | ||||
Negative | 114 (21%) | 91 (33%) | ||
Positive | 436 (79%) | 188 (67%) | ||
Unknown | 3 | 3 | ||
HER2 expression | ||||
Negative | 443 (82%) | 236 (86%) | ||
Positive | 95 (18%) | 37 (14%) | ||
Unknown | 15 | 9 | ||
Triple-negativee subtype | ||||
No | 483 (90%) | 232 (85%) | ||
Yes | 55 (10%) | 41 (15%) | ||
Unknown | 15 | 9 | ||
Histology | ||||
Ductal only | 492 (90%) | 226 (82%) | ||
Mixed ductal/lobular | 6 (1%) | 3 (1%) | ||
Lobular | 43 (8%) | 39 (14%) | ||
Other | 5 (1%) | 9 (3%) | ||
Unknown | 7 | 5 | ||
Stage | ||||
Localized (breast only) | 383 (69%) | 214 (76%) | ||
Regional (breast and regional nodes) | 162 (29%) | 62 (22%) | ||
Distant | 8 (2%) | 4 (2%) | ||
Unknown | 0 | 2 |